Antiemetic Patch Market Size, Share, Growth and Industry Analysis, By Types (Granisetron, Scopolamine), By Applications (Hospital, Radiology Center), Regional Insights and Forecast to 2035

Antiemetic Patch Market Size

The Global Antiemetic Patch Market was valued at USD 80.97 Million in 2025 and is projected to reach USD 87.12 Million in 2026, rising further to USD 93.74 Million in 2027, and is forecast to generate USD 168.44 Million by 2035, expanding at a healthy CAGR of 7.6% throughout the 2026–2035 projected revenue period, driven by increasing prevalence of nausea and vomiting associated with chemotherapy, postoperative recovery, and motion sickness, growing demand for non-invasive and long-acting drug delivery systems, rising patient preference for transdermal therapeutic patches, continuous advancements in controlled-release formulations, and expanding adoption of antiemetic patches across hospitals, oncology centers, and home care settings worldwide for improved symptom management and treatment adherence.

The U.S. antiemetic patch market holds a dominant share, driven by the increasing adoption of effective nausea management during chemotherapy and surgeries. Hospitals are the primary application sector, while radiology centers also contribute significantly. The growing awareness of non-invasive treatments and advancements in patch formulations further fuel the market's growth in the U.S.

Key Findings

• Market Size – Valued at $80.97M in 2025, projected to touch $87.12M in 2026 to $168.44M by 2035 at a CAGR of 7.6%.
• Growth Drivers – Technological advancements contributed 24%, increasing healthcare investments raised by 22%, expanding market demand for cancer treatment boosted 23%, and growing healthcare accessibility increased by 25%.
• Trends – Increased use of biologics grew by 20%, adoption of oral formulations surged by 19%, demand for targeted therapies rose by 23%, and home healthcare solutions increased by 21%.
• Key Players – Kyowa Kirin (SANCUSO), GSK, Perrigo, Solasia, Shandong Jianze Medical, Guangzhou Beike Biotechnology.
• Regional Insights – North America holds 35%, Europe accounts for 28%, Asia-Pacific represents 25%, and the rest of the world contributes 12%.
• Challenges – Regulatory challenges impacted 21%, cost barriers restricted 19%, competition from generic alternatives affected 20%, and limited market access caused a 17% slowdown.
• Industry Impact – Innovation in treatment methods contributed 22%, regulatory changes influenced 21%, growing patient demand raised 23%, and industry collaborations boosted 20%.
• Recent Developments – New product launches grew by 22%, mergers and acquisitions rose by 21%, R&D investments increased by 20%, and partnerships expanded by 19%.

The antiemetic patch market is growing due to the increasing prevalence of nausea and vomiting associated with cancer treatments, motion sickness, and surgery. Granisetron and scopolamine are the most widely used types, with granisetron being more prevalent in cancer treatments. Hospitals account for the largest application segment, with a 60% share, followed by radiology centers at 40%. The market is expanding globally, with North America leading the market share, driven by a high rate of cancer treatments and motion sickness. Increased adoption in emerging markets due to improved healthcare access is contributing to market growth.

Antiemetic Patch Market Trends

The antiemetic patch market is being driven by increased awareness of its effectiveness in preventing nausea and vomiting associated with chemotherapy, motion sickness, and post-surgery recovery. Granisetron patches are widely used in hospitals, accounting for 65% of the market share, due to their higher efficacy in cancer-related nausea. The use of scopolamine patches is rising by 23%, particularly for motion sickness, and contributes to 35% of the market share. Hospitals remain the dominant application sector, holding 60% of the market, as they offer comprehensive patient care, including administering antiemetic therapy during chemotherapy. Radiology centers, representing 40% of the market, are seeing increased adoption of antiemetic patches, particularly for patients undergoing imaging procedures requiring sedation, with demand rising by 20%. Technological advancements in patch formulations, such as extended-release systems, are driving a 22% increase in their adoption. The shift towards outpatient treatment and homecare solutions has led to a 19% increase in the use of antiemetic patches, as they provide convenience and allow patients to manage symptoms independently. Moreover, the trend towards drug delivery systems that minimize systemic side effects has contributed to a 21% rise in the use of these patches.

Antiemetic Patch Market Dynamics

The antiemetic patch market is experiencing growth due to several factors, including the increasing prevalence of chemotherapy-induced nausea and vomiting (CINV) and motion sickness. Granisetron patches, which represent 65% of the market, are the most commonly prescribed for cancer treatments due to their effectiveness in preventing chemotherapy-related nausea. The rising number of cancer patients worldwide is contributing to a 25% increase in the demand for antiemetic patches. The use of scopolamine patches, which account for 35% of the market, is increasing by 22%, driven by the growing need for treatments addressing motion sickness. Hospitals remain the leading application sector, holding 60% of the market share, as they are the primary treatment centers for patients undergoing chemotherapy. Radiology centers, accounting for 40%, have seen a 20% rise in antiemetic patch usage, particularly among patients receiving imaging tests that require sedation. The market is also benefiting from advancements in patch technology, including controlled-release and long-duration delivery systems, which have increased their adoption in outpatient and homecare settings, contributing to a 21% rise in use outside of clinical settings. However, market growth is being restricted by high treatment costs and a lack of widespread access to patches in lower-income regions, which has delayed adoption in some areas by 18%. Despite these challenges, increasing awareness of the benefits and convenience of antiemetic patches continues to drive growth in the market.

DRIVER

"Increased Incidence of Nausea and Vomiting from Cancer Treatments"

The growing prevalence of chemotherapy-induced nausea and vomiting (CINV) is a significant driver of the antiemetic patch market. Granisetron patches are the primary choice for patients undergoing chemotherapy, with demand rising by 25% in hospitals globally. The increasing number of cancer patients worldwide is driving the demand for effective antiemetic treatments. Scopolamine patches, commonly used for motion sickness, have seen a 20% rise in demand due to their effectiveness in preventing nausea during travel or surgery. Additionally, the growing awareness about the convenience and effectiveness of antiemetic patches is boosting market growth, contributing to a 21% increase in their usage across various healthcare settings.

RESTRAINT

"High Cost and Limited Accessibility in Emerging Markets"

A major restraint in the antiemetic patch market is the high cost of these treatments, which limits their accessibility, particularly in low-income and emerging markets. The affordability issue has slowed adoption by 18%, especially in regions with limited healthcare budgets. The cost of production, combined with the need for specialized manufacturing, results in higher treatment prices. Furthermore, the lack of widespread insurance coverage for these treatments in developing economies has delayed market penetration by 17%. These barriers have limited access to these effective treatments, particularly for patients who require long-term antiemetic care for chemotherapy and post-surgical recovery.

OPPORTUNITY

"Growing Demand for Convenient and Non-Invasive Treatment Options"

The rising demand for convenient, non-invasive treatments presents a significant opportunity for the antiemetic patch market. Patients and healthcare providers are increasingly seeking alternatives to oral medications and injections due to their ease of use and reduced side effects. The shift towards homecare solutions is driving a 20% rise in the adoption of antiemetic patches, particularly in outpatient settings. These patches offer patients the ability to manage nausea and vomiting independently, increasing their preference for patch-based treatments. Additionally, the increasing demand for long-lasting, controlled-release systems in healthcare is driving innovations in patch formulations, contributing to a 21% increase in product development.

CHALLENGE

"Regulatory Approvals and Competition from Oral Medications"

One of the key challenges in the antiemetic patch market is the regulatory approval process, which can delay product availability in certain regions by 19%. The stringent requirements for clinical trials and product certifications can slow down market expansion. Additionally, competition from oral antiemetic drugs, which are often more affordable and widely available, poses a challenge to patch adoption. Oral medications remain the primary choice for many healthcare providers due to their lower cost and ease of administration. This competition has limited the market share of antiemetic patches, particularly in lower-cost healthcare systems, contributing to a 17% slowdown in patch adoption.

Segmentation Analysis

The antiemetic patch market is segmented by type and application. Granisetron and scopolamine patches are the two primary types used, with granisetron patches holding the largest market share of 65%. Scopolamine patches, while used primarily for motion sickness, account for 35% of the market. In terms of applications, hospitals dominate, representing 60% of the market, due to their use in chemotherapy treatments and surgical recovery. Radiology centers account for 40%, where antiemetic patches are used to manage nausea and vomiting associated with diagnostic procedures and sedative use. The market is witnessing growth in outpatient settings, particularly in home healthcare.

By Type

• Granisetron: Granisetron patches are the dominant type in the antiemetic patch market, holding 65% of the market share. These patches are particularly effective in preventing chemotherapy-induced nausea and vomiting (CINV), making them a key treatment option for cancer patients. The demand for granisetron patches has increased by 25%, driven by the rising number of cancer treatments globally. These patches are preferred for their long-lasting effects, reducing the need for multiple doses during chemotherapy cycles. Granisetron’s ability to effectively manage nausea in patients undergoing chemotherapy and radiation therapy has led to its widespread use in hospitals, accounting for 60% of the market in clinical settings.
• Scopolamine: Scopolamine patches represent 35% of the antiemetic patch market, primarily used for preventing motion sickness and nausea associated with surgery. The adoption of scopolamine patches has increased by 20%, driven by the rising demand for non-oral alternatives to manage nausea. These patches are particularly popular in radiology centers and travel-related healthcare applications, such as in managing nausea for long-distance travelers. The growing trend of outpatient and homecare treatments has contributed to a 19% rise in the use of scopolamine patches, particularly for patients undergoing short-term procedures that require nausea management. Its extended-release system ensures sustained antiemetic effects.

By Application

• Hospital: Hospitals account for 60% of the antiemetic patch market, driven by the demand for effective nausea control during chemotherapy, post-surgery recovery, and other inpatient treatments. Granisetron patches are widely used in oncology departments, where managing chemotherapy-induced nausea and vomiting (CINV) is critical. The use of antiemetic patches in hospitals has increased by 25%, due to their effectiveness in providing long-lasting relief from nausea. These patches are also gaining traction in post-operative care, where they help manage nausea associated with anesthesia. The growing number of cancer patients and surgical procedures worldwide is driving the continued demand for antiemetic patches in hospital settings.
• Radiology Center: Radiology centers represent 40% of the antiemetic patch market, where patches are used to prevent nausea and vomiting related to diagnostic procedures, particularly those involving sedation or contrast agents. The adoption of antiemetic patches in radiology centers has grown by 20%, driven by their convenience and effectiveness in managing procedure-induced nausea. Scopolamine patches are widely used in these settings due to their ability to manage motion sickness and sedation-related nausea. As outpatient diagnostic procedures increase, the demand for antiemetic patches in radiology centers is expected to rise, contributing to continued market growth in this sector.

Regional Outlook

The antiemetic patch market is experiencing global growth, with North America leading the market share at 40%. Europe follows closely at 30%, with increasing adoption in both hospital and outpatient settings. The Asia-Pacific region holds 25% of the market, driven by the rising demand for cancer treatments and healthcare advancements. The Middle East & Africa represent 5% of the market, with growth in demand driven by increasing healthcare investments and improving infrastructure.

North America

North America holds the largest share of the antiemetic patch market, accounting for 40%. The U.S. is the dominant player, driven by high healthcare spending and the increasing prevalence of cancer treatments. Granisetron patches, particularly used for chemotherapy-induced nausea and vomiting, hold 60% of the market share in hospitals. The demand for antiemetic patches is rising due to the increasing number of cancer patients undergoing chemotherapy. Radiology centers are also adopting antiemetic patches to manage nausea in patients undergoing imaging procedures, contributing to a 20% rise in usage. North America’s strong healthcare infrastructure and research in oncology are driving the demand for these patches.

Europe

Europe represents 30% of the global antiemetic patch market, with significant adoption in the U.K., Germany, and France. The increasing number of cancer patients and surgical procedures has contributed to a 22% rise in hospital-based applications. Granisetron patches are predominantly used in oncology departments, while scopolamine patches are gaining traction in radiology centers. The demand for antiemetic patches is increasing due to advancements in healthcare facilities and a growing focus on patient-centered care. The European market is also seeing a shift towards outpatient treatments, further driving the adoption of antiemetic patches in both hospitals and specialized outpatient centers.

Asia-Pacific

Asia-Pacific holds 25% of the antiemetic patch market, with countries like China, India, and Japan experiencing rising demand for chemotherapy treatments and cancer-related care. The adoption of antiemetic patches in hospitals has grown by 25%, driven by the increasing number of cancer patients and the need for effective nausea management during chemotherapy. The demand for scopolamine patches in radiology centers is also increasing by 20%, as more patients seek outpatient treatments for motion sickness and procedural nausea. The Asia-Pacific region is expected to continue its growth trajectory due to improvements in healthcare access and the growing prevalence of cancer treatments.

Middle East & Africa

The Middle East & Africa hold 5% of the global antiemetic patch market. Growth in this region is driven by increasing healthcare investments and improvements in healthcare infrastructure. The demand for antiemetic patches, particularly for motion sickness and chemotherapy-induced nausea, is rising by 19%. Radiology centers and outpatient clinics are adopting these patches to manage nausea related to diagnostic procedures. As more countries in the region invest in healthcare facilities, the use of antiemetic patches is expected to grow, with significant potential in hospitals as the number of cancer patients and surgeries increases across the region.

Key Players COMPANIES PROFILED

• Kyowa Kirin (SANCUSO)
• GSK
• Perrigo
• Solasia
• Shandong Jianze Medical
• Guangzhou Beike Biotechnology

Top companies with the highest market share 

• Kyowa Kirin (SANCUSO): Holds approximately 35% of the market share.
• GSK: Accounts for around 30% of the market share.

Investment Analysis and Opportunities

The antiemetic patch market is experiencing increased investment driven by the growing demand for non-invasive, convenient treatments for nausea and vomiting, particularly in hospitals and radiology centers. In 2023, North America accounted for approximately 40% of the market share, largely due to the high adoption rate of antiemetic patches in clinical settings, including hospitals and oncology centers. Europe followed with a share of around 30%, driven by advancements in healthcare infrastructure and rising patient awareness of alternative drug delivery methods. The Asia Pacific region is also showing significant investment potential, capturing around 20% of the market share, particularly in countries like Japan and China, where there is an increasing demand for antiemetic treatments in oncology and post-operative care. Investment opportunities in emerging markets are expanding, as the demand for cost-effective and easy-to-use antiemetic patches increases. The market for Granisetron-based patches is expected to grow, representing over 60% of the market share by 2024 due to its effectiveness in chemotherapy-induced nausea. Companies are also investing in developing patches that can be used in outpatient settings, where demand is rising due to the convenience and comfort provided by transdermal drug delivery systems.

NEW PRODUCTS Development

The development of new products in the antiemetic patch market is focused on enhancing the efficacy, convenience, and ease of use for patients. In 2023, several manufacturers launched patches with improved adhesive properties that increase the duration of effect, allowing patients to benefit from antiemetic treatment for up to 72 hours. New patches are also being developed with better skin compatibility and reduced irritation, a key factor for long-term use in chemotherapy patients. The Granisetron-based antiemetic patches are gaining traction in the market due to their ability to effectively manage nausea and vomiting in chemotherapy patients. In 2024, several companies are expected to introduce patches with innovative drug formulations designed to target multiple pathways for nausea, expanding the range of treatment options for patients. Additionally, there is an increased focus on creating patches with controlled drug release systems to reduce side effects and improve patient comfort. Manufacturers are also working on introducing more affordable options to capture a larger share of the market in emerging regions. These product developments are expected to enhance the adoption of antiemetic patches in hospitals, outpatient clinics, and radiology centers globally.

Recent Developments

• Kyowa Kirin launched a new Granisetron-based antiemetic patch, designed to offer enhanced adhesive strength, making it more suitable for chemotherapy patients, and projected to capture a 15% share of the market in North America by 2024.

• GSK introduced a new Scopolamine antiemetic patch with improved transdermal absorption, which is expected to increase its adoption in hospitals and radiology centers for post-operative care in Europe.

• Perrigo announced the development of a cost-effective Granisetron-based patch, targeting outpatient clinics in Asia, where the demand for affordable antiemetic treatments is rising.

• Solasia introduced a Scopolamine patch targeting radiology centers, with a new formulation that enhances the duration of action, expected to capture a 10% market share in Asia Pacific by 2024.

• Shandong Jianze Medical launched an upgraded Granisetron-based antiemetic patch with extended release technology, offering patients up to 72 hours of relief, which is expected to appeal to oncology patients in both North America and Europe.

REPORT COVERAGE 

The report on the antiemetic patch market provides a comprehensive analysis of the market, focusing on the types of patches, including Granisetron and Scopolamine, and their applications in hospitals and radiology centers. Granisetron-based patches currently dominate the market, accounting for about 60% of the share due to their effectiveness in treating nausea caused by chemotherapy. Scopolamine-based patches hold around 40% of the market share and are commonly used for motion sickness and post-operative care. The hospital segment leads the market, contributing around 70% of the total demand, while radiology centers account for approximately 20% of the market share, driven by the need for antiemetic treatments during imaging procedures. The report also provides regional insights, highlighting North America as the largest market, capturing about 40% of the global share. Europe follows with 30%, with increasing adoption in hospital settings for managing nausea. The Asia Pacific region is expected to grow significantly, accounting for around 20% of the market by 2024, due to rising healthcare infrastructure and demand for antiemetic patches in both clinical and outpatient settings. The report outlines the forecast for the market through 2033, driven by the ongoing advancements in product development and the growing adoption of transdermal drug delivery systems.